Lindus Therapeutics is in-licensing external assets and developing them through to value inflection points.

Lindus Therapeutics is a next-generation drug development company. We advance portfolios of in-licensed assets, pairing our asset identification and selection capability with an integrated clinical trial delivery platform. Domain experts work hand in glove with proprietary AI systems that enable us and our partners to reach value inflection points faster and more efficiently than the industry standard. Lindus is backed by investors and advisors including Peter Thiel and Bob Langer.